Trials / Recruiting
RecruitingNCT07363590
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
A Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1045 in Participants With Systemic Lupus Erythematosus and Rheumatoid Arthritis
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study looks at a study medicine called MK-1045 in people with lupus and rheumatoid arthritis (RA). The main goal of the study is to learn about the safety of MK-1045 and if people tolerate it when they receive it at different dose levels (amounts).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MK-1045 | IV infusion |
Timeline
- Start date
- 2026-02-19
- Primary completion
- 2029-07-16
- Completion
- 2029-07-16
- First posted
- 2026-01-23
- Last updated
- 2026-04-01
Locations
4 sites across 4 countries: Belgium, Georgia, Italy, Moldova
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07363590. Inclusion in this directory is not an endorsement.